Cancer Biopsy Market Overview

The Cancer Biopsy Market is projected to witness significant growth from 2025 to 2035, driven by the increasing incidence of cancer. Valued at approximately USD 34.1 billion in 2025, the market is expected to surge to USD 77.5 billion by 2035, reflecting a strong compound annual growth rate (CAGR) of 7.7% over the ten-year period.

A cancer biopsy is a diagnostic tool where tissue or cell samples are removed from a suspected tumor and examined under the microscope to confirm the existence of cancer. It helps determine the type of cancer, stage, and aggressiveness and guides decisions on treatment and outcome. There are several biopsies, each suited to different clinical situations. Needle biopsies include fine-needle aspiration (FNA), where fluid or cells are suctioned off using a fine needle, and core needle biopsy (CNB), where more tissue is removed.

Surgical biopsies involve excisional biopsy, where the tumor is removed and examined, and incisional biopsy, where some of it is removed and tested. There is endoscopic biopsy, where a flexible tube fitted with a camera is inserted to enter organs inside the body, and liquid biopsy, where cancer markers are found in body fluids like blood through a minimally invasive method. The major applications of cancer biopsies are not diagnostic alone.

They are critical when it comes to cancer staging, as they indicate how advanced the disease is, and this dictates the treatments. Treatment protocols also rely on biopsies, as they allow doctors to select targeted treatments, chemotherapy, or immunotherapy based on tumor markers. They are also used to measure response to therapy, to determine that the therapy is successful. With the advent of liquid biopsies, biopsies are now used to diagnose cancers early and screen them, as they provide non-invasive ways of detecting malignancies early.

Furthermore, genetic profiling from biopsies has made personalized medicine possible, whereby treatments are tailored to the patient based on their own genetic mutations. Through proper diagnosis, staging, and monitoring of therapies, biopsies remain the cornerstone of oncology, significantly contributing to improved patient care and outcomes.

Cancer Biopsy Market Drivers and Opportunities

Rising Prevalence of Colorectal Cancer and Gastrointestinal Disorders is anticipated to lift the Cancer Biopsy Market during the forecast period

​One of the key drivers of the cancer biopsy market is the increasing global incidence of cancer. Cancer is one of the leading causes of death, and millions are diagnosed annually, according to the World Health Organization (WHO). In 2022, 20 million new cancer cases and 9.7 million deaths were estimated. 53.5 million people survived 5 years from diagnosis. About 1 in 5 people develop cancer at some point in their lives, and about 1 in 9 men and 1 in 12 women die from the disease.

Rise in cancer incidence is driving demand for early and correct diagnostic solutions, as early diagnosis and treatments are enhancing survival and treatment rates. Conventional biopsies, i.e., needle and surgical biopsies, are still very much relevant, while liquid biopsy is becoming increasingly popular due to its non-invasive nature and ability to detect cancer at an early stage. The growing focus on regular cancer screening programs, particularly among advanced nations, is also driving the growth of the market.

Advancements in Biopsy Technologies

Sustained advancements in cancer biopsy technologies are significantly contributing to market growth. Liquid biopsy, artificial intelligence-based pathology, and next-generation sequencing (NGS) are all contributing to the accuracy, speed, and efficiency of cancer diagnosis. Liquid biopsy is particularly revolutionizing cancer diagnosis by allowing circulating tumor DNA (ctDNA) and circulating tumor cells (CTCs) to be identified from a non-invasive blood draw. These technologies are lowering the need for invasive procedures, reducing patient discomfort, and allowing cancer progression and response to therapy to be followed in real-time. In addition, the application of AI to the analysis of biopsies is increasing the accuracy of cancer detection, lowering diagnostic errors, and optimizing workflow efficiency in pathology labs.

Opportunity for the Cancer Biopsy Market

Growing Adoption of Personalized Medicine is significant opportunities in the global Cancer Biopsy Market

One of the key growth opportunities of the cancer biopsy market is the growing demand for personalized medicine. With oncologic therapies becoming more targeted, there is an increasing demand for biopsies that provide information regarding the genetic and molecular composition of the tumor. Biomarker-based diagnosis forms the cornerstone of personalized medicine, and it makes treatments personalized to the cancer type of an individual, maximizing the efficacy of therapy and minimizing side effects.

Liquid biopsy, in particular, is making precision oncology possible by allowing tumor tracking in real-time without putting patients through repeated invasive testing. Pharmaceutical companies and clinicians are increasingly emphasizing personalized treatments, and this demand is expected to drive advanced biopsy technologies, opening high-value growth opportunities.

Cancer Biopsy Market Scope

Cancer Biopsy Market Report Segmentation Analysis

The global Cancer Biopsy Market industry analysis is segmented into by Product, by type of Biopsy, by Application, by End-user and by region.

The Kits and Consumables segment is anticipated to hold the major share of the global Cancer Biopsy Market during the projected timeframe.

Kits and Consumables are set to dominate the largest share of the global cancer biopsy market as demand for the procedure increases and disposable products are frequently used. Consumables, including biopsy needles, reagents, and collection tubes, are essential to sample collection, storage, and analysis, and hence create stable demand from all health facilities.

Rise in the use of liquid biopsy, wherein specialized consumables are utilized to detect circulating tumor DNA (ctDNA) and extracellular vesicles, is also propelling growth in the market. In addition, advancements in molecular diagnostics and personalized medicine are generating demand for high-quality biopsy kits that enable accurate detection of cancer biomarkers.

The Needle Biopsy segment is anticipated to hold the highest share of the global Cancer Biopsy Market during the projected timeframe.

Needle Biopsy segment is poised to hold the largest market share as it is minimally intrusive and highly accurate. Fine needle aspiration biopsy (FNAB) and core needle biopsy (CNB) are frequently used to diagnose cancers of the breast, lung, and prostate. Rising incidence of these cancers and popularity of outpatient treatments that avoid hospitalization are fuelling demand for needle biopsy. In addition, use of imaging modalities such as ultrasound and MRI-guided needle biopsies is increasing accuracy and fuelling growth.

The Breast Cancer application segment is anticipated to hold the highest share of the market over the forecast period.

Breast Cancer application segment would hold the largest share as the occurrence of breast cancer is increasing around the world. Detection at an early stage by means of biopsy processes is crucial to maximize survival. Liquid biopsy and needle biopsy are commonly used to diagnose and monitor breast cancer, allowing for better decision-making during treatments. Growth is also spurred by the increasing use of genetic testing and analysis of biomarkers.

The Hospital & Clincis end-user segment dominated the market in 2024 and is predicted to grow at the highest CAGR over the forecast period.

Hospitals & Clinics segment had the highest share of the market in 2024 and is expected to grow at the highest Compound Annual Growth Rate (CAGR) as sophisticated biopsy technologies and skilled health professionals are easily accessible. Hospital and specialized cancer clinics perform most of the biopsies as they are equipped with advanced diagnostic machinery and labs. The growth of the segment is also driven by the growing number of cancer treatment centers and government initiatives to promote early detection of cancer.

The following segments are part of an in-depth analysis of the global Cancer Biopsy Market:

Cancer Biopsy Market Share Analysis by Region

North America is projected to hold the largest share of the global Cancer Biopsy Market over the forecast period.

North America is expected to account for the highest share of the global cancer biopsy market during the forecast period due to high incidence of cancer, advanced health infrastructure, and increasing use of advanced diagnostic technologies. The American Cancer Society estimates that about 2 million cancer cases would be diagnosed in the United States alone during 2024, and the most prevalent cancers are lung, breast, prostate, and colorectal. The increasing incidence of cancer is fuelling demand for early and precise diagnostic technologies, including liquid biopsy, fine needle aspiration biopsy, and core needle biopsy. Liquid biopsy, particularly, is gaining traction due to its non-invasive method and ability to detect cancer at an early stage, further driving market growth.

Additionally, North America is supported by strong government funding and support for cancer research and the presence of key market players that are investing in biopsies. The region also has an established reimbursement system that facilitates access to advanced biopsies, and this promotes extensive use. There is also increasing demand toward personalized medicine and targeted treatments that are driving demand for precise biopsies to identify genetic mutations and tumor markers.

Cancer Biopsy Market Competition Landscape Analysis

The market is competitive, with several established players and new entrants offering a range of cancer biopsy products. Some of the key players QIAGEN, Epigenomics AG, BD (Becton, Dickinson and Company), Biocept, Inc., F. Hoffmann-La Roche Ltd., Danaher and others.

Global Cancer Biopsy Market Recent Developments News:

In May 2024, Inocras and IMBdx announced that they are joining forces to promote enhanced cancer patient care in the United States. Through this partnership, Inocras, the whole genome sequencing diagnostic solutions leader, and IMBdx, the leader in liquid biopsy-based cancer diagnosis, can provide more solutions to cancer patients and their doctors.

In April 2023, Quest Diagnostics and Haystack Oncology, an early-stage oncology company working on developing minimal residual disease (MRD) testing to facilitate early and accurate identification of residual or recurrent cancer and more informed therapy choices, announced they had signed a definitive agreement whereby Quest would acquire Haystack through an all-cash equity transaction.

In March 2021, Agilent Technologies Inc. announced that it signed a definitive agreement to acquire Resolution Bioscience Inc., the leader in developing and commercializing next-generation sequencing (NGS)-based precision oncology solutions. The acquisition expands and complements Agilent’s strengths in NGS-based cancer diagnostics and adds innovative technology to the company to continue to serve the needs of the expanding precision medicine market.

The Global Cancer Biopsy Market is dominated by a few large companies, such as

·         QIAGEN

·         Epigenomics AG

·         BD (Becton, Dickinson and Company)

·         Biocept, Inc.

·         Danaher

·         Exact Sciences Corporation

·         F. Hoffmann-La Roche Ltd.

·         Freenome Holdings, Inc.

·         GRAIL, Inc.

·         Guardant Health Inc.

·         Hologic, Inc.

·         Illumina, Inc.

·         Lucence Health Inc.

·         Myriad Genetics, Inc.

·         Thermo Fisher Scientific, Inc.